The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: Application of a new model in India and Israel

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 26, Issue 8, 2013, Pages 802-810

  Marseille, Elliot ^a   Lohse, Nicolai ^b   Jiwani, Aliya ^a   Hod, Moshe ^c   Seshiah, Veeraswamy ^d   Yajnik, Chittaranjan S ^e   Arora, Geeti Puri ^f   Balaji, Vijayam ^d   Henriksen, Ole ^g   Lieberman, Nicky ^h   Chen, Rony ^c   Damm, Peter ⁱ   Metzger, Boyd E ^j   Kahn, James G ^k  

^a Health Strategies International   (United States)

^b NOVO NORDISK A S   (Denmark)

^c TEL AVIV UNIVERSITY   (Israel)

^d Dr Balaji Diabetes Care Centre   (India)

^e KEM HOSPITAL   (India)

^f Deep Hospital   (India)

^g Last Mile P S   (Denmark)

^h CLALIT HEALTH SERVICES   (Israel)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j NORTHWESTERN UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Cost effectiveness analysis; Costs; Diagnosis; Gestational diabetes mellitus; Management; Type 2 diabetes mellitus

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION TREE; FEMALE; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH IMPACT ASSESSMENT; HEALTH MAINTENANCE ORGANIZATION; HUMAN; INDIA; ISRAEL; NEWBORN DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PRIORITY JOURNAL; RISK REDUCTION; SCREENING; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; HUMANS; INDIA; ISRAEL; MASS SCREENING; PREGNANCY; PRENATAL CARE;

EID: 84876559824     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2013.765845     Document Type: Article

References (43)

1. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.
2. Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol 2005;192:989-97. (Pubitemid 40487770)
3. Keshavarz M, Cheung NW, Babaee GR, et al. Gestational diabetes in Iran: incidence, risk factors and pregnancy outcomes. Diabetes Res Clin Pract 2005;69:279-86. (Pubitemid 41140108)
4. Yang X, Hsu-Hage B, Zhang H, et al. Women with impaired glucose tolerance during pregnancy have significantly poor pregnancy outcomes. Diabetes Care 2002;25:1619-24. (Pubitemid 41071121)
5. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and metaanalysis. Lancet 2009;373:1773-9.
6. Dabelea D, Hanson RL, Lindsay RS, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes 2000;49:2208-11.
7. Clausen TD, Mathiesen ER, Hansen T, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care 2008;31:340-6. (Pubitemid 351213348)
8. Jiwani A, Marseille E, Lohse N, et al. Gestational diabetes mellitus: results from a survey of country prevalence and practices. J Matern Fetal Neonatal Med 2012;25:600-10.
9. Agarwal MM, Dhatt GS, Shah SM. Gestational diabetes mellitus: simplifying the international association of diabetes and pregnancy diagnostic algorithm using fasting plasma glucose. Diabetes Care 2010;33:2018-20.
10. Poncet B, Touzet S, Rocher L, et al. Cost-effectiveness analysis of gestational diabetes mellitus screening in France. Eur J Obstet Gynecol Reprod Biol 2002;103:122-9. (Pubitemid 34586783)
11. Werner EF, Pettker CM, Zuckerwise L, et al. Screening for gestational diabetes mellitus: are the criteria proposed by the international association of the diabetes and pregnancy study groups cost-effective? Diabetes care 2012;35:529-35
12. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications; 1997:305.
13. Santos-Ayarzagoitia M, Salinas-Martinez AM, Villarreal-Perez JZ. Gestational diabetes: validity of ADA and WHO diagnostic criteria using NDDG as the reference test. Diabetes Res Clin Pract 2006;74:322-8. (Pubitemid 44572561)
14. World Bank. World Development Report 1993: investing in health. New York (NY): Oxford University Press; 1993.
15. Round JA, Jacklin P, Fraser RB, et al. Screening for gestational diabetes mellitus: cost-utility of different screening strategies based on a woman's individual risk of disease. Diabetologia 2011;54:256-63.
16. Culligan PJ, Myers JA, Goldberg RP, et al. Elective cesarean section to prevent anal incontinence and brachial plexus injuries associated with macrosomia-a decision analysis. Int Urogynecol J Pelvic Floor Dysfunct 2005;16:19-28; discussion 28. (Pubitemid 40109750)
17. Horvath K, Koch K, Jeitler K, et al. Effects of treatment in women with gestational diabetes mellitus: systematic review and metaanalysis. BMJ 2010;340:c1395.
18. Siribaddana SH, Deshabandu R, Rajapakse D, et al. The prevalence of gestational diabetes in a Sri Lankan antenatal clinic. Ceylon Med J 1998;43:88-91.
19. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862-8.
20. Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008;93:4774-9.
21. World Health Organization. Life Tables for WHO Member States. 2012. Available from http://www.who.int/healthinfo/statistics/mortality-life-tables/ en/[last accessed 29 Jan 2013].
22. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England J Med 2002;346:393-403. (Pubitemid 34437694)
23. Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-97. (Pubitemid 43185397)
24. Wendland EM, Duncan BB, Mengue SS, Schmidt MI. Lesser than diabetes hyperglycemia in pregnancy is related to perinatal mortality: a cohort study in Brazil. BMC Preg Childbirth 2011;11:92.
25. Gonzalez JC, Walker JH, Einarson TR. Cost-of-illness study of type 2 diabetes mellitus in Colombia. Pan Am J Pub Health 2009;26:55-63.
26. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002;25:476-81. (Pubitemid 41103339)
27. Dall TM, Mann SE, Zhang Y, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag 2009;12:103-10.
28. Gilmer TP, Roze S, Valentine WJ, et al. Cost-effectiveness of diabetes case management for low-income populations. Health Serv Res 2007;42:1943-59. (Pubitemid 47397181)
29. Zhuo X, Zhang P, Hoerger T. Lifetime cost of type 2 diabetes in the US. Diabetes Pro-Professional Resources Online. Alexandria (VA): American Diabetes Association; 2010.
30. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002;45:S5-12. (Pubitemid 34762208)
31. Nolan JJ, O'Halloran D, McKenna TJ, et al. The cost of treating type 2 diabetes (CODEIRE). Irish Med J 2006;99:307-10.
32. Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of Type II diabetes. Diabetologia 2001;44:2140-55. (Pubitemid 34015466)
33. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
34. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ Journal Assoc Med Canadienne 2009;180:400-7.
35. USRDS Coordinating Center. December 21. United States Renal Data System (USRDS). Available from: http://www.usrds.org/%3E [last accessed 21 December 2011].
36. Ashkenazy R, Abrahamson MJ. Medicare coverage for patients with diabetes. A national plan with individual consequences. J Gen Internal Med 2006;21:386-92.
37. World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE): Cost-effectiveness thresholds. 2011. Available from: http://www.who.int/choice/costs/CER-thresholds/en/index.html [last accessed 29 Jan 2013].
38. Central Intelligence Agency. The World Fact Book. 2011. In COUNTRY COMPARISON: GDP-PER CAPITA (PPP). Available from: https://http://www.cia.gov/ library/publications/theworld-factbook/rankorder/2004rank.html%3E [last accessed 9 July 2011].
39. Ramachandran K, van Wert J, Gopisetty G, Singal R. Developmentally regulated demethylase activity targeting the betaA-globin gene in primary avian erythroid cells. Biochemistry 2007;46:3416-22. (Pubitemid 46449160)
40. Diabetes Prevention Program Research G. Within-trial costeffectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003;26:2518-23.
41. Ben-Haroush A, Glickman H, Yogev Y, et al. Induction of labor in pregnancies with suspected large-for-gestational-age fetuses and unfavorable cervix. Eur J Obstet Gynecol Reprod Biol 2004; 116:182-5. (Pubitemid 39195131)
42. World Health Organization.World Health Statistics 2011. Available from: http://www.who.int/whosis/whostat/2011/en/index.html [last accessed 29 Jan 2013].
43. Lauenborg J, Hansen T, Jensen DM, et al. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care 2004;27:1194-9. (Pubitemid 38579789)